Pancreatic Cancer Research

ResearcherUniversity of PaduaActive in the last 2 years

Samuele Grandi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9257-0240; OpenAlex author ID A5002854828, A5031920271. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
27
Papers, trials and grants by year

2023: 1 paper · 2024: 2 papers · 2025: 2 papers · 2026: 3 papers

Papers 8

  1. The projected rise of pancreatic cancer mortality in Italy: forecasts until 2035. Co-author DOI 10.1007/s13304-026-02862-w↗
  2. Incidence and consequences of chyle leak after pancreatectomy for pancreatic cancer. Co-author DOI 10.1016/j.hpb.2025.10.004↗
  3. Conversion surgery vs. standard of care in pancreaTic cancer oligometastatic to the liver (SONAR: Surgery in Oligometastatic paNcreatic cAnceR) a randomized co… Co-author DOI 10.1186/s12885-025-15183-9↗
  4. Complications following upfront pancreatectomy with venous resection do not compromise adjuvant chemotherapy delivery and survival in pancreatic cancer. First author DOI 10.1007/s00423-025-03933-z↗
  5. Prediction of early recurrence as a marker of surgical futility in pancreatic adenocarcinoma. Co-author DOI 10.1016/j.suronc.2025.102208↗
  6. Characteristics and prognosis of patients with pancreatic adenocarcinoma not expressing CA19-9: Analysis of the National Cancer Database. Co-author DOI 10.1016/j.pan.2024.11.011↗
  7. Neoadjuvant Chemotherapy Versus Upfront Surgery for Resectable Pancreatic Adenocarcinoma: An Updated Nationwide Study. Co-author DOI 10.1097/sla.0000000000005925↗
  8. Association of Adjuvant Chemotherapy in Patients With Resected Pancreatic Adenocarcinoma After Multiagent Neoadjuvant Chemotherapy. Co-author DOI 10.1001/jamaoncol.2022.5808↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Giampaolo Perri · 3 shared papers, 2025–2026 · strength 0.87
  2. Umberto Cillo · 3 shared papers, 2025–2026 · strength 0.87
  3. Giovanni Marchegiani · 3 shared papers, 2025–2026 · strength 0.87
  4. Toshitaka Sugawara · 4 shared papers, 2023–2026 · strength 0.84
  5. Jun Ishida · 4 shared papers, 2023–2026 · strength 0.84
  6. Richard David Schulick · 4 shared papers, 2023–2026 · strength 0.84
  7. Oskar Franklin · 3 shared papers, 2024–2026 · strength 0.67
  8. Ana Gleisner · 3 shared papers, 2023–2024 · strength 0.56
  9. Marco Del Chiaro · 3 shared papers, 2023–2024 · strength 0.56
  10. Riccardo Guastella · 2 shared papers, 2025–2026 · strength 0.49
  11. Patrick Maisonneuve · 1 shared paper, 2026 · strength 0.39
  12. Marco Del Chiaro · 1 shared paper, 2026 · strength 0.28
  13. Andrii Khomiak · 1 shared paper, 2026 · strength 0.28
  14. Thomas F. Stoop · 1 shared paper, 2026 · strength 0.28
  15. Hiroyuki Ishida · 1 shared paper, 2026 · strength 0.28
  16. Letizia Procaccio · 1 shared paper, 2026 · strength 0.26
  17. Sara Lonardi · 1 shared paper, 2026 · strength 0.26
  18. Francesca Bergamo · 1 shared paper, 2026 · strength 0.26
  19. Zipeng Lu · 1 shared paper, 2025 · strength 0.23
  20. Davide Citterio · 1 shared paper, 2025 · strength 0.23
  21. Andrea Zironda · 1 shared paper, 2025 · strength 0.23
  22. Michele Mazzola · 1 shared paper, 2025 · strength 0.23
  23. Vincenzo Mazzaferro · 1 shared paper, 2025 · strength 0.23
  24. Giovanni Carlo Ferrari · 1 shared paper, 2025 · strength 0.23
  25. Giuseppe Leoncini · 1 shared paper, 2025 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.